Find Funding Opportunities

The National Institutes of Health (NIH) Office of Nutrition Research (ONR) and participating NIH Institutes and Centers (ICs) intend to publish a Funding Opportunity Announcement (FOA) for new applications that will support new institutional research training programs (predoctoral, postdoctoral or both) in artificial intelligence (AI) for precision nutrition (AIPrN) that will focus on integration of the domains of precision nutrition, AI including machine learning (ML), systems biology, systems science, Big Data, and computational analytics. The goal is to build a future workforce that will be able to use growing data resources to tackle complex biomedical challenges in nutrition science that are beyond human intuition. It is hoped such research will lead to the development of innovative solutions to combat diet-related chronic diseases within the mission areas of the participating ICs. The vision of the AIPrN training program is to support the development of a diverse research workforce capable who will possess advanced competencies in AI including machine learning and data science analytics to apply to an increasingly complex landscape of Big Data from the molecular, to organismal, to community and societal scales related to nutrition and diet related conditions.

The purpose of this limited competition Funding Opportunity Announcement is to allow UDN Clinical Sites that received an NIH award under RFA-RM-17-019 an opportunity to compete for one additional year of NIH funding to: continue their participation in the UDN; establish collaborations and efficient processes with the next phase Data Management and Coordinating Center (DMCC; see: RFA-NS-22-051), enroll and evaluate new participants; and develop further their sustainability plans.

The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science.

The National Institutes of Health (NIH) HEAL (Helping to End Addiction Long-termSM) Initiative intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting applications for UG3/UH3 phased cooperative research to accelerate implementation of evidence-based, non-opioid interventions for chronic pain management in rural and remote populations. Interventions addressing acute pain in rural and remote populations are also responsive if the acute pain requires the intervention of a health care provider for management, such as acute dental pain or acute low back pain and are likely to recur, become chronic, or escalate to a more serious complication if not managed appropriately. Projects include pragmatic, implementation or hybrid effectiveness-implementation trials to improve pain management and reduce the unnecessary use of opioid medications. Awards made under this FOA will initially support a milestone-driven, planning phase (UG3) of 1 to 2 years, with possible transition to a study conduct phase (UH3) of up to 3-4 years duration (5 years total for the two phases). Only UG3 projects with a planned pilot may request 2 years for the planning phase with up to 3 years for the UH3 implementation phase.in the community. All other projects may request 1 year for the UG3 phase with up to 4 years for the UH3 phase. UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase.

This BRAIN Initiative FOA is to further develop molecular tools of high impact that are targetable to brain cell types for the monitoring and manipulation of neural circuits in experimental animals. This FOA is part of the BRAIN Initiative Armamentarium for Brain Cell Access transformative project. This will support iterative improvement of molecular payloads capable of monitoring and manipulating neural cell activity and that can be delivered to specific brain cell types using targeting technologies.

NINDS will no longer participate in both FOAs after 9/27/22 receipt date.

The NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative intends to issue RFA-EB-22-001, BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in summer 2022 with an expected application due date in fall 2022 This FOA will utilize the UG3/UH3 activity code. Details of the planned FOA are provided below.

The National Institute on Drug Abuse (NIDA) intends to solicit proposals from qualified organizations (NAICS Code 541715) having in-house capability to support and provide resources to the participating grantees for completing biocompatibility studies, in vivo animal testing compliant with good laboratory (GLP) guidelines, and sterilization and shelf life testing. This contractor will provide support for research protocol development, research staff training, and conduct all testing necessary to support biocompatibility, sterilization, and animal safety studies.

The National Institute on Drug Abuse (NIDA) intends to solicit proposals from qualified organizations (NAICS Code 541715) having in-house capability to support and provide resources to the participating grantees for completing clinical feasibility studies of novel medical devices in the neurotechnology field. The clinical studies may include both feasibility and larger safety and efficacy assessments in patients affected by the condition being studied. BPMT anticipates running 5 to 15 clinical studies per year over the next 5 years. Most, but not all, are likely to be NIH-defined Clinical Trials https://grants.nih.gov/policy/clinical-trials/definition.htm.

The purpose of this notice is to move the first receipt date to July 15, 2022.